These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 8472530)

  • 1. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
    Shcherbakov AB
    Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
    Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Raynaud's phenomenon: diagnostic and therapeutic aspects].
    Soro P; Occhioni G; Spissu M; Trignano M; Dettori G; Bacciu PP; Biglioli P
    Chir Ital; 1981 Jun; 33(3):647-60. PubMed ID: 7307205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational use of calcium-channel antagonists in Raynaud's phenomenon.
    Sturgill MG; Seibold JR
    Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
    Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
    Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.
    Thompson AE; Pope JE
    Rheumatology (Oxford); 2005 Feb; 44(2):145-50. PubMed ID: 15546967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.